Physician profile
Jack A Stroh
NPI 1356347066
$62,243.74
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $36K · 2020: $14K · 2021: $11K · 2022: $765 · 2023: $584 · 2024: $16.14.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $600.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $599.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $31,177.60 | 2019-2020 | |
| Esperion Therapeutics, INC. | $9,717.33 | 2020-2023 | Nexletol |
| Sanofi-Aventis U.S. LLC | $6,494.54 | 2019 | |
| Medtronic Vascular, INC. | $5,789.35 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $5,175.55 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $941.97 | 2019-2023 | Eliquis |
| Janssen Pharmaceuticals, INC | $816.91 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $470.63 | 2019-2024 | |
| Abbott Laboratories | $445.63 | 2019-2020 | |
| Pfizer INC. | $257.50 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $209.68 | 2021-2023 | Verquvo |
| Abiomed | $203.31 | 2019-2023 | Impella |
| Boston Scientific Corporation | $148.70 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $129.83 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $120.35 | 2019-2023 | Jardiance |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $52.16 | 2019-2021 | |
| Amgen INC. | $44.66 | 2019-2023 | Repatha |
| Medtronic, INC. | $20.18 | 2022 | |
| Gilead Sciences, INC. | $14.91 | 2019 | |
| Edwards Lifesciences Corporation | $12.95 | 2023 | Sapien 3 Ultra Resilia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Stroh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.